Table 2.
FACS Analysis on BMA and cBMA from the MarrowStim P.A.D. Kit (n = 6)
| CD marker | Function and cell type | BMA (%) | cBMA (%) |
|---|---|---|---|
| R1 gate | Lymphocytes | 17.4 ± 6.6 | 20.5 ± 3.5 |
| R2 gate | Monocytes | 4.0 ± 1.2 | 4.3 ± 1.5 |
| R3 gate | Granulocytes | 75.5 ± 5.8 | 71.2 ± 7.2 |
| VEGFR-2 | Tyrosine kinase receptor (endothelial cells and precursors) | 5.6 ± 1.8 | 7.5 ± 3.2 |
| CD3 | Antigen receptor (T cells) | 9.0 ± 3.3 | 11.5 ± 2.9 |
| CD14 | Surface glycoprotein (monocytes and macrophages) | 5.4 ± 2.5 | 4.8 ± 3.3 |
| CD34 | Transmembrane glycoprotein (hematopoietic and endothelial progenitor cells) | 0.9 ± 1.0 | 1.0 ± 0.6 |
| CD45 | Transmembrane protein tyrosine kinase (white blood cells and hematopoietic stem cells) | 91.1 ± 4.9 | 90.7 ± 6.6 |
| CD56 | NCAM-1 (heparin-binding glycoprotein; T cells) | 8.3 ± 8.5 | 7.7 ± 5.8 |
| CD105 | TGF-β receptor, endoglin (SH2; endothelial cells, monocytes, macrophages, a subpopulation of hematopoietic stem cells, and cultured mesenchymal stem cells) | 4.1 ± 3.4 | 9.3 ± 16.1 |
| CD117 | Tyrosine kinase receptor (hematopoietic stem cells, B cells, and T cells) | 3.2 ± 5.5 | 1.8 ± 1.2 |
| CD133 | Trasmembrane protein (hematopoietic stem cells and endothelial cells) | 0.2 ± 0.1 | 0.2 ± 0.1 |
| Stro-1 | Bone marrow stromal cells | 0.8 ± 0.6 | 1.1 ± 0.6 |
There were no significant differences between the BMA and the cBMA for all markers analyzed, except for the VEGFR-2 receptor (p = 0.04).
FACS, fluorescence-activated cell sorting; TGF-β, transforming growth factor-β.